Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Expressionist® for Mass Spectrometry will be showcased in the “Establishing Analytical Support for Manufacturing” session of the 2013 Biotherapeutics Analytical Summit. The session will present workflows for analyzing glycosylation events using Genedata Expressionist. The Genedata platform automates and standardizes protein characterization within a single high-throughput system to significantly improve sample throughput and result reproducibility. The presentation will be given on March 13 (Royal Sonesta Harbor Court) by Dr. Monica Lane from Genzyme.
Genedata Expressionist for Mass Spectrometry is a comprehensive, enterprise software solution that efficiently manages, processes and analyzes massive amounts of mass spectrometry data. With a proven track record of success in the biopharmaceutical industry, it analyzes mass spectrometry data for a variety of tasks related to protein characterization, such as identification and quantification of Post Translational Modifications (PTMs). Instrument-agnostic, Genedata Expressionist integrates and analyzes raw data from any mass spectrometry technology and vendor, serving as an integration platform for analytical labs using a variety of mass spectrometry instruments. By automating routine data analysis, Genedata Expressionist has been successfully applied along the biopharmaceutical R&D and manufacturing pipelines to improve quality control and sample analytics.
Standardized Platform Accelerates Research – Reduces Research Costs
Thriving on large experimental data sets, Genedata Expressionist has been proven to reduce data analysis time from weeks to a few hours. By enhancing productivity, improving data quality and accelerating time-to-market, Genedata Expressionist contributes to significant cost savings by several orders of magnitude.
The Genedata session at the Biotherapeutics Analytical Summit will demonstrate how leading pharmaceutical companies have successfully automated the analysis of mass spectrometry data for site-specific glycosylation of biopharmaceuticals. The qualitative and quantitative analysis of glycosylation presents data analysis challenges, which Genedata Expressionist solves with a platform for fast comparability of biotherapeutic batches, ensuring consistent manufacturing processes.
“Genedata Expressionist for Mass Spectrometry provides our customers with a highly valuable platform that automates the processing of mass spec data in the context of characterizing biotherapeutics,” noted Dr. Othmar Pfannes, CEO of Genedata. “In particular, our solution’s innovative visualizations enable quick and reproducible decision making. The elimination of data analysis bottlenecks generates tremendous cost and time savings, making Genedata Expressionist nothing short of a killer application for the bioanalytics industry,” continued Pfannes.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.